Major Rating Factors:
A history of deficient reserves (2.7 on a scale of 0 to 10) that places pressure on both capital and profits. In 2023 and 2024 the two year reserve development was 28.5% and 33.2% deficient respectively. Weak profitability index (2.1) with operating losses during 2023, 2024 and the first six months of 2025. Average return on equity over the last five years has been poor at -8.5%. Good long-term capitalization index (6.0) based on fair current risk adjusted capital (moderate loss scenarios), although results have slipped from the good range over the last two years.
Other Rating Factors:
Fair overall results on stability tests (3.6) including negative cash flow from operations for 2024 and fair risk adjusted capital in prior years. Good liquidity (6.9) with sufficient resources (cash flows and marketable investments) to handle a spike in claims.
Stability Factors:
C - Past results on our Risk-Adjusted Capital tests.
D - Limited diversification of general business, policy, and/or investment risk.
F - Negative cash flow.
T - Significant trends in critical asset, liability, income or expense items.
Principal Lines of Business:
Med mal (99.8%), other (0.2%)
Licensed in:
FL, MD, NJ, OH, PA, SC, WV
Principal Investments:
Investment grade bonds (79.7%), common stock (12.7%), cash (6.1%), other (1.5%)
Corporate Info
Group Affiliation
None
Investment Rating
--
Company Address
41909 Route 6
Wyalusing, PA 18853
Wyalusing, PA 18853
Phone Number
(570) 746-9429
NAIC Number
11694
Website
Largest Affiliates
No affiliate information available.